a subset of patients complain that their memory and concentration is not as sharp after receiving treatment for solid tumours. This problem persists in some patients, but there is no correlation between self-reported impairment and cognitive impairment detected on formal neuropsychological testing. Self-reported cognitive impairment is strongly associated with fatigue, anxiety and depression, but these symptoms are not correlated with objective impairment. Cross-sectional studies found that 15-50% of oncology patients have impairment after chemotherapy, with prospective studies reporting that up to 30% of patients have cognitive impairment before chemotherapy. apart from the treatment of anxiety and depression, there is no proven intervention to prevent longterm impairment or to treat it once it has occurred.
Introduction
There is growing evidence that a subset of people who survive cancer suffer cognitive impairment after chemotherapy. 1, 2, 3, 4, 5, 6 Survivors have coined the terms 'chemobrain' and 'chemofog' to describe this symptom, although recent studies have found that some patients' cognitive impairment may predate the chemotherapy 7 , and hormonal treatment for cancer may also impact on cognitive function. 6, 8 Fortunately, the problem is generally subtle and often improves after ceasing chemotherapy. However, for some survivors the symptoms are 
Self-reported impairment
Multiple studies have reported no significant association between cognitive impairment after chemotherapy on formal cognitive testing and patients' self-report of their cognitive function. The patient's perception of cognitive impairment is generally worse than that detected by objective assessment. 1, 2, 3, 5, 6 The literature indicates consistently that there is a strong association between self-reported cognitive impairment and fatigue, anxiety and depression. 2, 6, 11 However, no association has been found between these symptoms and objective cognitive impairment. 1,2,3,4,6,9,11 Regardless of the reason for the dissociation between self-reported cognitive impairment and cognitive impairment detected on formal neuropsychological tests, any impairment can cause substantial distress. 5 
Potential mechanisms
The cause of cognitive impairment in cancer patients after chemotherapy is unknown, but is likely to be multifactorial.
Possible mechanisms by which chemotherapy might lead to cognitive dysfunction include:
n direct neurotoxic effects n oxidative damage n induced hormonal changes n immune deregulation with release of cytokines n blood clotting in small vessels of the central nervous system. Some patients may have a genetic predisposition to developing cognitive impairment (for example, due to problems with DNA or neuronal repair, changes in neurotransmitter activity or apolipoprotein ε4 genotype). 12 Preliminary results of two studies suggest that elevated cytokines may be associated with increased cognitive dysfunction and fatigue.
Chemotherapy regimen and dose-related toxicity
It is likely that the regimen, the dose and the duration of chemotherapy influence the incidence and severity of cognitive impairment. 12 The different regimens may account for the varying rates of incidence reported in the published studies.
In particular, objective rates of impairment have been higher following treatment with cyclophosphamide, methotrexate another study found no significant difference between high-dose and standard-dose chemotherapy. 13 
Duration of impairment
The duration of cognitive impairment after anticancer treatment is uncertain. One study of breast cancer and lymphoma found more cognitive dysfunction in patients up to 10 years after chemotherapy, compared to patients who had surgery or radiotherapy without chemotherapy. 1 A Dutch study reported impairment in breast cancer patients at a median of 1.9 years after chemotherapy 3 , but no difference between groups four years after treatment. 14 Longer-term follow-up of longitudinal studies is required to determine the duration of impairment.
Treatment of cognitive impairment after chemotherapy
There are no proven interventions to prevent chemotherapyassociated cognitive impairment or to treat it once it has developed. Randomised controlled trials have investigated the use of prophylactic erythropoietin and methylphenidate, however all trials were essentially negative. Other small intervention studies are ongoing, but it is difficult to design an intervention until we have a better understanding of mechanisms. At present the mainstay of treatment for patients with self-reported cognitive impairment is to treat any existing depression and anxiety.
Although there is no published research of cognitive rehabilitation programs in cancer survivors, cognitive rehabilitation has been shown to be effective in treating other patient groups with cognitive impairment. 15, 16 Different interventions have been developed, but the majority of methods focus on either restoration of a specific cognitive function (for example, attention training) or compensatory training to help patients adapt to the presence of deficits, rather than trying to treat the underlying deficit. 16 A small interim analysis of a behaviour therapy program has shown some potential benefit, however further results are awaited.
Conclusion
Approximately a third of cancer patients have cognitive impairment before receiving chemotherapy and possibly 20-30% have cognitive impairment after chemotherapy. The underlying mechanism of the impairment is currently unknown.
Once we have insight into the mechanisms that might cause cognitive impairment, strategies for preventing or minimising chemotherapy-induced cognitive impairment can be devised.
